According to the World Health Organization (WHO), the uncontrolled growth and spread of chronic diseases have created a great discrepancy in the life expectancy rate, and this is mainly due to a lack of diagnostics. More than one-third of total deaths are because of the absence of a proper first line of defense, i.e., diagnosis of the disease. In regard to in-vitro diagnostic (IVD) products, digital polymerase chain reaction (d-PCR) has done significantly great work, along with the process of innovation and evolution in d-PCR technology. Digital PCR was developed to provide high precision, absolute quantification with a wide range of applications for both research and clinical diagnostics applications. This d-PCR system has been divided into droplet-based and chip-based platform technology. With the increasing number of patients undergoing testing, there has been a consistent evolution of technologies increasing the sensitivity of disease diagnosis, and an overall approach toward precision medicine has created tremendous opportunities for digital PCR-based diagnostic testing. 


This technology has demonstrated various applications such as oncology (in tumor diagnosis), copy number variation, non-invasive prenatal testing, rare disease detection, and deoxyribonucleic acid (DNA) rearrangement. For instance, in the case of non-invasive prenatal testing, the highly sensitive nature of digital PCR makes the detection of sparsely suspended cell-free fetal DNA (cffDNA) in maternal plasma possible. This process is used to detect genetic diseases that can be detected prenatally and are easy to predict at a genetic level. Prenatal testing involves the detection of single-gene inheritance disease, autosomal recessive disorders, and chromosome aneuploids, among others. 


Digital PCR Market is projected to reach $2,847.8 million by 2032 from $441.2 million in 2021, at a CAGR of 18.73% during the forecast period 2022-2032. The growth in the global digital PCR market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases globally, the rising awareness of d-PCR-based diagnostic testing, and the significant number of funding for executing research and development.


Market Opportunities


Extensive Adoption of Genetic Testing, especially in Developing Nations 


The current market prospects indicate an underlying dominance of genetic tests that can facilitate and impact treatment decisions. The accessibility of high-precision diagnostic tests, especially molecular tests for genetic disorders, is focused on around the world. Despite the fact there have been significant strides into progressing biomarker-based tests and their consequent adoption into routine healthcare methodologies, there is an absence by individuals in low-income countries. However, major key players such as Fluidigm Corporation, QIAGEN N.V., and Genetron Holdings Limited are identifying these emerging regions as highly untapped, which makes them a perfect fit to expand their business and create more awareness leading to the significant growth of the market.


Market Footprint and Growth Potential 


Significant investments by companies to meet industry demand, the growing adoption of digital PCR among major end users, and the increasing prevalence of chronic diseases are the major factors propelling the growth of the global digital PCR market. 


Get Free Sample Report - Click Here


Key Questions Answered in the Report 


▪ How is digital PCR revolutionizing the field of genomics? 

▪ What are the major market drivers, challenges, and opportunities in the global digital PCR market? 

▪ What are the underlying structures resulting in the emerging trends within the global digital PCR market? 

▪ How did the COVID-19 pandemic impact the global digital PCR market? 

▪ What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market? 

▪ What are the key regulatory implications in developed and developing regions pertaining to the use of digital PCR? 

▪ What are the potential entry barriers that are expected to be faced by the companies willing to enter a particular region? 

▪ How is each segment of the market expected to grow during the forecast period 2022-2032, and what is the anticipated revenue to be generated by each of the segments?